Racke M - Search Results

1

Basal Ganglia Iron in Patients with Multiple Sclerosis Measured with 7T Quantitative Susceptibility Mapping Correlates with Inhibitory Control.

Schmalbrock P, Prakash RS, Schirda B, Janssen A, Yang GK, Russell M, Knopp MV, Boster A, Nicholas JA, Racke M, Pitt D. Schmalbrock P, et al. Among authors: racke m. AJNR Am J Neuroradiol. 2016 Mar;37(3):439-46. doi: 10.3174/ajnr.A4599. Epub 2015 Nov 26. AJNR Am J Neuroradiol. 2016. PMID: 26611996 Free PMC article.

2

The potential role of B cell-targeted therapies in multiple sclerosis.

Boster A, Ankeny DP, Racke MK. Boster A, et al. Drugs. 2010 Dec 24;70(18):2343-56. doi: 10.2165/11585230-000000000-00000. Drugs. 2010. PMID: 21142258 Review.

3

Multiple sclerosis: Five new things.

Nicholas JA, Boster AL, Racke MK. Nicholas JA, et al. Neurol Clin Pract. 2013 Oct;3(5):404-412. doi: 10.1212/CPJ.0b013e3182a78f94. Neurol Clin Pract. 2013. PMID: 24175156 Free PMC article.

4

Design of oral agents for the management of multiple sclerosis: benefit and risk assessment for dimethyl fumarate.

Nicholas JA, Boster AL, Imitola J, O'Connell C, Racke MK. Nicholas JA, et al. Drug Des Devel Ther. 2014 Jul 7;8:897-908. doi: 10.2147/DDDT.S50962. eCollection 2014. Drug Des Devel Ther. 2014. PMID: 25045248 Free PMC article. Review.

5

New and Emerging Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis: What is New and What is to Come.

Nicholas J, Morgan-Followell B, Pitt D, Racke MK, Boster A. Nicholas J, et al. Among authors: racke mk. J Cent Nerv Syst Dis. 2012 May 16;4:81-103. doi: 10.4137/JCNSD.S6692. Print 2012. J Cent Nerv Syst Dis. 2012. PMID: 23650470 Free PMC article.

6

Lessons learned from fatal progressive multifocal leukoencephalopathy in a patient with multiple sclerosis treated with natalizumab.

Boster AL, Nicholas JA, Topalli I, Kisanuki YY, Pei W, Morgan-Followell B, Kirsch CF, Racke MK, Pitt D. Boster AL, et al. JAMA Neurol. 2013 Mar 1;70(3):398-402. doi: 10.1001/jamaneurol.2013.1960. JAMA Neurol. 2013. PMID: 23338729 Review.

7

Concise review: modeling multiple sclerosis with stem cell biological platforms: toward functional validation of cellular and molecular phenotypes in inflammation-induced neurodegeneration.

Orack JC, Deleidi M, Pitt D, Mahajan K, Nicholas JA, Boster AL, Racke MK, Comabella M, Watanabe F, Imitola J. Orack JC, et al. Among authors: racke mk. Stem Cells Transl Med. 2015 Mar;4(3):252-60. doi: 10.5966/sctm.2014-0133. Epub 2015 Jan 15. Stem Cells Transl Med. 2015. PMID: 25593207 Free PMC article. Review.

8

First-line natalizumab in multiple sclerosis: rationale, patient selection, benefits and risks.

Nicholas JA, Racke MK, Imitola J, Boster AL. Nicholas JA, et al. Ther Adv Chronic Dis. 2014 Mar;5(2):62-8. doi: 10.1177/2040622313514790. Ther Adv Chronic Dis. 2014. PMID: 24587891 Free PMC article. Review.

9

Efficacy, safety, and cost-effectiveness of glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis.

Boster A, Bartoszek MP, O'Connell C, Pitt D, Racke M. Boster A, et al. Among authors: racke m. Ther Adv Neurol Disord. 2011 Sep;4(5):319-32. doi: 10.1177/1756285611422108. Ther Adv Neurol Disord. 2011. PMID: 22010043 Free PMC article.

10

Pharmacotherapy of multiple sclerosis: the PROOF trial.

Boster A, Racke MK. Boster A, et al. Expert Opin Pharmacother. 2009 Jun;10(8):1235-7. doi: 10.1517/14656560902927856. Expert Opin Pharmacother. 2009. PMID: 19463066

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

231 results

Search Page

Filters